English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Funding Acknowledgements Type of funding sources: None. Background Although long-term use of HCQ and AZT has been reported to cause QT prolongation and malign arrhythmia, there is not enough data about the effect of short-term use on arrhythmia. Purpose: The aim of this study was to assess the effect of HCQ alone and HCQ + AZT on corrected QT (QTc).Methods: A baseline ECG and on-treatment ECGs were retrospectively collected in COVID-19 patients who received HCQ and/or AZT. Also peak QTc intervals of monotherapy and combination therapy was compared. Results: Of the 155 patients included, 102 (65.8%) were using HCQ, 53 (34.2%) were using HCQ + AZT combination. The use of both HCQ alone and HCQ + AZT combined therapy significantly prolonged the QTc and the QTc interval was significantly longer in patients received combination therapy. QTc prolongation caused early termination in both groups, 5 (4.9%) patients in the monotherapy group and in 6 (11.3%) patients in the combined therapy group.Conclusion: Patients who received HCQ for COVID-19 were at high risk of QTc prolongation, and concurrent treatment with AZT was associated with greater changes in QTc. Comparison of baseline characteristics a Characteristic Total (n = 155) Hydroxychloroquine (n = 102) Hydroxychloroquine /Azithromycin (n = 53) P value Length of stay at ward, SD 9.54 ± 4.28 9.64 ± 4.31 9.31 ± 4.25 0.88 Length of stay Intensive care unite,SD 7.92 ± 3.76 7.18 ± 3.18 8.46 ± 4.15 0.29 Radiographic findings of pneumonia 118(76.1%) 76(74.5%) 42(49.2%) 0.32 Mechanically ventilation 16(10.3%) 7(6.9%) 9(17.0%) 0.049 In hospital death 19(12.3%) 10(9.8%) 9(17.0%) 0.15 ECG findings median(IQR) (ms) Baseline QRS duration 91.0(80.0-103.0) 92.5(80.75-105.50) 90.0(80.0-102.5) 0.5 Posttreatment QRS peak 97.0(86.0-109.0) 97.5(88.0-109.25) 95.0(85.5-109) 0.68 ΔQRS 4.0(0.0-9.0) 2.0(0.0-8.25) 5.0(1.0-9.5) 0.14 Baseline QTc duration 407.0(385.0-426.0) 408.0(389.25-427.50) 404.0(384.0-420.0) 0.1 Posttreatment QTc peak 437.0(414.0-460.0) 428.0(412.75-449.25) 456.0(422.0-467.5) &amp;lt;0.001 ΔQTc 27.0(13.0-45.0) 18.0(11.0-30.0) 46.0(40.5-54.5) &amp;lt;0.001 Baseline PR duration 145.50(128.7-160.0) 147.0(135.0-160.0) 144.0(120.0-160.0) 0.53 Posttreatment PR peak 159.0(140.0-170.0) 159.0(141.0-168.50) 156.0(139.5-171.0) 0.97 ΔPR 7.0(1.0-13.0) 5.0(0.0-12.25) 10.0(5.0-15.0) 0.022 QTc peak day 5.0(4.0-5.0) 5.0(4.0-6.0) 4.0(3.0-5.0) 0.022 Drug withdrawl due to QRS prolongation 11(7.1%) 5(4.9%) 6(11.3%) 0.12

The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel coronavirus disease 2019